NRG-LU005 Trial: Atezolizumab Plus Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer
oncodaily - A major international clinical trial, NRG-LU005, has provided important new insight into how immunotherapy should be used in limited-stage small cell lung cancer (SCLC). While immune checkpoint inhibitors have significantly […]
AI Summary: A major international trial tested whether adding the PD‑L1 inhibitor atezolizumab to concurrent chemoradiotherapy for limited‑stage small‑cell lung cancer would boost outcomes. The study found no significant survival benefit, prompting clinicians to rethink the timing and role of immune checkpoint blockade in curative‑intent SCLC rather than assuming more drugs always means better results.
Related Stories
HORMAD1 emerges as a potential target in triple‑negative breast cancer / 5 months
Roche’s hoped‑for breast cancer pill fails crucial first‑line trial / 5 months
Romiplostim prevents chemo-induced platelet crashes in phase 3 trial / 5 months
ENZAMET trial confirms long-term survival benefit of enzalutamide in mHSPC / 8 days
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 1 month
Teclistamab shows survival benefit prompting earlier use discussions / 2 months
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Novo Nordisk, Corporate Takeover, Avian Influenza, Pfizer and look for the RSS link.
StackHealth Time Machine